2013
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Kang J, Irwin D, Chen-Plotkin A, Siderowf A, Caspell C, Coffey C, Waligórska T, Taylor P, Pan S, Frasier M, Marek K, Kieburtz K, Jennings D, Simuni T, Tanner C, Singleton A, Toga A, Chowdhury S, Mollenhauer B, Trojanowski J, Shaw L, Lasch S, Flagg E, Poewe W, Sherer T, Meunier C, Rudolph A, Casaceli C, Seibyl J, Mendick S, Schuff N, Uribe L, Yankey J, Crawford K, Scutti A, Casalin P, Malferrari G, Hawkins K, Russell D, Leary L, Factor S, Sommerfeld B, Hogarth P, Pighetti E, Williams K, Standaert D, Guthrie S, Hauser R, Jankovic J, Hunter C, Stern M, Darin A, Leverenz J, Baca M, Frank S, Thomas C, Richard I, Deeley C, Rees L, Sprenger F, Oertel W, Willeke D, Shill H, Fernandez H, Mule J, Berg D, Gauss K, Galasko D, Fontaine D, Mari Z, McCoy A, Brooks D, Shah B, Barone P, Isaacson S, James A, Espay A, Espay K, Rowe D, Ranola M. Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease. JAMA Neurology 2013, 70: 1277-1287. PMID: 23979011, PMCID: PMC4034348, DOI: 10.1001/jamaneurol.2013.3861.Peer-Reviewed Original ResearchConceptsDrug-naive patientsEarly Parkinson's diseaseCSF biomarkersΒ-amyloid 1CSF Aβ1-42P-tau181Parkinson's diseaseT-tauAβ1-42Healthy controlsΑ-synucleinClinical featuresPPMI cohortParkinson's Progression Markers Initiative (PPMI) studyLower CSF Aβ1-42Early-stage Parkinson's diseaseT-tau/Aβ1Lower Aβ1-42P-tau181 concentrationsCSF t-tauΑ-synuclein levelsCerebrospinal fluid levelsCross-sectional studyEnzyme-linked immunosorbent assaySignificant correlation
2010
Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD)
Russell D, Jennings D, Tamagnan G, Seibyl J, Koren A, Zubal G, Marek K. Poster 14: Evaluation of Novel Radiotracers Targeting Non-Dopaminergic Striatal Biomarkers in HD: 18F-FPEB and PET Imaging for Metabotropic Glutamate Receptor Type 5 (mGluR5) Expression in Healthy Subjects and Subjects with Huntington Disease (HD). Neurotherapeutics 2010, 7: 142. DOI: 10.1016/j.nurt.2009.09.016.Peer-Reviewed Original ResearchHD subjectsHuntington's diseaseMGluR5 expressionTemporal lobeHuman studiesStandardized uptake value ratioPET imagingEnkephalinergic striatal neuronsLimbic cortical areasMean SUV ratioEarly brain changesEarly HD patientsUptake value ratioGray matter areasPromising PET radiotracerCerebellar reference regionSymptomatic HD subjectsNon-human primatesHD patientsNeuron lossStriatal neuronsIntense uptakeHealthy controlsBrain changesAge 44